View Featured Categories
GLP-1 for PCOS: The Hormone Signal Rewriting the Playbook
Women's Health · PCOS
GLP-1 for PCOS may be a useful option for women whose condition is driven by insulin resistance and excess weight. In trials summarized in a 2023 review, liraglutide and exenatide were linked to weight loss, less visceral and liver fat, lower free testosterone, better ovulation, and higher prediabetes remission rates.
Picture a woman who does everything right.
She tracks her meals. She walks after dinner. She swapped soda for sparkling water two years ago and never looked back.
Still, the scale barely moves. Her cycle shows up when it wants. Her doctor keeps using one phrase she has come to dread: insulin resistance.
If that sounds familiar, you are far from alone. Polycystic ovary syndrome, or PCOS, is the most common hormone disorder in women of reproductive age. It affects an estimated 6% to 20% of them. For many women, the frustration is not lack of effort.
It may be biology.
The Problem Under the Surface
PCOS is usually defined by two main signs: higher androgen levels and irregular or absent ovulation. But a 2023 review in the Journal of Clinical Medicine, led by Aleksandra Szczesnowicz and Blazej Meczekalski, argues that the metabolic side deserves far more attention.
Consider the numbers the authors gathered:
By the review's estimate, at least half of women with PCOS also have obesity, about three times the rate in women without PCOS.
Lifestyle change remains the first-line approach. Diet, exercise, and behavioral support keep showing up in the research, and they are the foundation of most natural PCOS management strategies. The problem is staying with it. In one lifestyle study the review cites, dropout rates among women with PCOS ranged from 12% to 47%.
That is where a gut hormone comes in.
How GLP-1 for PCOS Works
Glucagon-like peptide-1, or GLP-1, is a natural hormone released after you eat. It tells the pancreas to release insulin, but only when blood sugar is high. GLP-1 drugs for PCOS mimic that signal. The review names semaglutide, liraglutide, and exenatide as examples, and these medications come in more than one form, which our guide to injectable vs. oral GLP-1s walks through.
How GLP-1 Drugs Act
- They slow stomach emptying.
- They increase fullness and lower hunger.
- They suppress glucagon, which raises blood sugar.
- They help the body release insulin when glucose is high.
For women with PCOS, that mix may target the metabolic knot at the center of the condition. In short, GLP-1 and PCOS research is focused on PCOS insulin resistance, weight, and hormone balance.
What the PCOS Trials Found
The review pulls together a growing set of studies in women with PCOS. Three stand out.
| Study | Participants | Treatment | Key Results |
|---|---|---|---|
| 26-week trial (Frøssing et al.) | 72 women with PCOS and excess weight | Liraglutide 1.8 mg daily vs. placebo | More than 5% weight loss; liver fat −44%; visceral fat −18%; free testosterone −19% |
| Prediabetes trial | 150 women with PCOS and prediabetes | Exenatide + metformin, exenatide alone, or metformin alone | Remission rates of 64%, 56%, and 32% |
| Six-month ultrasound study | Women with PCOS | Liraglutide vs. placebo | Notable drop in ovarian volume; no change in excess hair growth |
In a liraglutide PCOS weight loss trial that lasted 26 weeks, 72 women with PCOS and excess weight took liraglutide, 1.8 mg daily, or placebo. The liraglutide group lost more than 5% of body weight. Liver fat fell 44%. Deep belly, or visceral, fat dropped 18%. Free testosterone declined 19%.
That matters because free testosterone sits near the core of PCOS.
In another trial, 150 women with PCOS and prediabetes were studied. Remission rates were 64% with exenatide plus metformin, 56% with exenatide alone, and 32% with metformin alone.
A six-month study that followed the ovaries by ultrasound found that liraglutide was linked to a clear drop in ovarian volume compared with placebo. Excess hair growth did not change during that short period, which the authors say may reflect the short treatment time.
The review's authors summed it up this way:
"Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a new addition to the therapeutic arsenal for the metabolic management of PCOS."
— Szczesnowicz et al., Journal of Clinical Medicine, 2023Fertility: Promise, With a Pause
GLP-1 fertility and PCOS research points to a possible fertility angle. In the trials reviewed by the authors, exenatide, alone or with metformin, improved menstrual cycles and ovulation rates in women with PCOS and excess weight. One comparison also found more spontaneous pregnancies with exenatide than with metformin after 24 weeks.
That said, there is an important pause. The review says there is no conclusive safety data on GLP-1 drugs during pregnancy. Women using them are advised to use effective contraception and allow a washout period before trying to conceive.
Who May Be a Candidate
GLP-1 drugs are not right for everyone. In the review, the main use in PCOS is for women with a BMI over 30, or over 27 with a related issue such as high blood pressure, abnormal cholesterol, sleep apnea, or prediabetes. A clinician would also screen for factors that may make treatment a poor fit, including a history of pancreatitis, certain thyroid cancers, eating disorders, and other medical concerns.
The most common side effects are digestive, mainly nausea and diarrhea. They are often strongest early on, so doctors usually raise the dose slowly.
And the science keeps moving. Retatrutide, an experimental drug that targets GLP-1 plus two other hormone receptors, helped participants lose about 30% of body weight over roughly 80 weeks, according to manufacturer trial data reported by UCHealth.
Back to the Woman Who Does Everything Right
Her effort was never the problem. For many women with PCOS, the problem is a metabolic system that pushes back. GLP-1 research offers a new, evidence-based way to understand that resistance, and a new set of questions to bring to a doctor who knows PCOS well.
The Frøssing results and the prediabetes findings are only part of the story. The full review also covers how doctors screen, dose, and monitor treatment week by week. You can read the full GLP-1 and PCOS review in the Journal of Clinical Medicine.
Frequently Asked Questions About GLP-1 for PCOS
Are GLP-1 medications a replacement for lifestyle changes in PCOS?
Not according to the research summarized here. Lifestyle change, including diet, exercise, and behavioral support, remains the first-line approach for PCOS. GLP-1 medications are discussed as a possible added tool for certain patients, especially when obesity, prediabetes, or insulin resistance is present and a qualified healthcare provider decides they are appropriate.
Can you take GLP-1 drugs while trying to get pregnant?
Caution is advised. Some studies suggest improvements in menstrual cycles, ovulation, and spontaneous pregnancy rates, but the review notes there is no conclusive safety data for GLP-1 drugs during pregnancy. Women using these medications are advised to use effective contraception and allow a washout period before trying to conceive, under medical guidance.
What are the most common side effects of GLP-1 drugs?
The most common side effects are digestive, especially nausea and diarrhea. They are often strongest at the start of treatment, which is why doctors usually increase the dose gradually instead of starting high.
Effort Isn't the Missing Piece
For many women with PCOS, insulin resistance makes progress harder than effort alone can explain. In the trials summarized by Szczesnowicz and colleagues, GLP-1 drugs were linked to meaningful changes in weight, visceral fat, free testosterone, ovulation, and prediabetes remission. They are best viewed as a possible addition to lifestyle care, chosen with a clinician who knows PCOS well.
You Might Also Be Interested In
References
- McCrimmon, K. K. (2026, June 16). Retatrutide, the newest weight-loss drug, helped people lose 30% of body weight, on par with weight-loss surgery. UCHealth Today. UCHealth.
- Szczesnowicz, A., Szeliga, A., Niwczyk, O., Bala, G., & Meczekalski, B. (2023). Do GLP-1 analogs have a place in the treatment of PCOS? New insights and promising therapies. Journal of Clinical Medicine, 12(18), 5915. doi.org/10.3390/jcm12185915.
The trial results described here come from specific clinical trials summarized in Szczesnowicz et al. (2023). Individual results vary. GLP-1 receptor agonists are prescription medicines that need evaluation by a qualified healthcare provider. Retatrutide is investigational and not FDA-approved. Per UCHealth (2026), its findings came from manufacturer data that had not undergone peer review, and the report does not address PCOS. This content is for informational purposes only and is not medical advice. It does not replace care from a qualified healthcare professional. Always talk with your doctor before starting, stopping, or changing any medication or treatment.
